Exercise tolerance in patients with idiopathic pulmonary fibrosis IPF is mainly limited by mechanical constrain of ventilation and high physiologic dead space. Oxygen enriched gas inhalation seems to increase ventilatory efficiency by reduction of dead space to tidal volume ratio (VD/VT) which probably mirrors improved pulmonary capillary flow and leads to longer physical tolerance at lower level of minute ventilation. The effect is noticeable at FIO2 that can be delivered in rehabilitation purposes or daily living activities.

Department of Respiratory Diseases Thomayer Hospital 1st Faculty of Medicine Charles University Prague Czech Republic

See more in PubMed

Agusti C, Xaubet A, Agusti AGN, Roca J, Ramirez J, Rodriguez-Roisin R. Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: Results of a 3 year follow-up. Eur Respir J. 1994;7(4):643–650. doi: 10.1183/09031936.94.07040643. PubMed DOI

DiMarco AF, Kelsen SG, Cherniack NS, Gothe B. Occlusion pressure and breathing pattern in patients with interstitial lung disease. Am Rev Respir Dis. 1983;127(4):425–430. doi: 10.1164/arrd.1983.127.4.425. PubMed DOI

Schaeffer MR, Ryerson CJ, Ramsook AH, et al. Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. Eur Respir J. 2018;51:1701726. doi: 10.1183/13993003.01726-2017. PubMed DOI

Agustí AGN, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez-Roisin R. Mechanisms of Gas-exchange Impairment in Idiopathic Pulmonary Fibrosis. Am Rev Respir Dis. 1991;143(2):219–225. doi: 10.1164/ajrccm/143.2.219. PubMed DOI

Hallstrand TS, Boitano LJ, Johnson WC, Spada C, Hayes JG, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J. 2005;25(1):96–103. doi: 10.1183/09031936.04.00137203. PubMed DOI

Arizono S, Furukawa T, Taniguchi H, Sakamoto K, Kimura T, Kataoka K, Ogawa T, Watanabe F, Kondoh Y. Supplemental oxygen improves exercise capacity in IPF patients with exertional desaturation. Respirology. 2020;25(11):1152–1159. doi: 10.1111/resp.13829. PubMed DOI

Miki K, Maekura R, Hiraga T, Okuda Y, Okamoto T, Hirotani A, Ogura T. Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. Respir Med. 2003;97(5):482–490. doi: 10.1053/rmed.2002.1469. PubMed DOI

Bell EC, Cox NS, Goh N, Glaspole I, Westall GP, Watson A, Holland AE. Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev. 2017;26(143):160080. doi: 10.1183/16000617.0080-2016. PubMed DOI PMC

Schaeffer, Michele R, Molgat-Seon Y, Ryerson, Christopher J, Guenette JA. Suplemental oxygen and dyspnoea in interstitial lung disease: absence of evidence is not evidence of absence. Eur Respir J. 2017;26:170033. doi: 10.1183/16000617.0033-2017. PubMed DOI PMC

Hansen JE, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest. 1996;109(6):1566–1576. doi: 10.1378/chest.109.6.1566. PubMed DOI

Radtke T, Crook S, Kaltsakas G, et al. ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases. Eur Respir Rev. 2019;28(154):180101. doi: 10.1183/16000617.0101-2018. PubMed DOI PMC

Plantier L, Cazes A, Dinh-Xuan AT, Bancal C, Marchand-Adam S, Crestani B. Physiology of the lung in idiopathic pulmonary fibrosis. Eur Respir Rev. 2018;27(147):170062. doi: 10.1183/16000617.0062-2017. PubMed DOI PMC

Troy LK, Young IH, Lau EMT, Corte TJ. Exercise pathophysiology and the role of oxygen therapy in idiopathic interstitial pneumonia. Respirology. 2016;21(6):1005_14. doi: 10.1111/resp.12650. PubMed DOI

Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: Connecting the dots. Am J Respir Crit Care Med. 2007;175(9):875–880. doi: 10.1164/rccm.200608-1153CC. PubMed DOI

Ward SA. Ventilation/carbon dioxide output relationships during exercise in health. Eur Respir Rev. 2021;30:200160. doi: 10.1183/16000617.0160-2020. PubMed DOI PMC

Idiopathic Pulmonary Fibrosis: Review of Current Knowledge

Adipose tissue-derived mesenchymal stem cells attenuate lung inflammation and fibrosis in the bleomycin-induced pulmonary fibrosis rat model via caveolin-1/NF-kB signaling axis